Navigation Links
DURECT Corporation Announces Third Quarter 2008 Financial Results
Date:11/3/2008

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2008. Total revenues were $6.6 million for the three months ended September 30, 2008, compared to $4.9 million for the same period in 2007. Net loss for the three months ended September 30, 2008 was $9.2 million, compared to a net loss of $7.9 million for the same period in 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

At September 30, 2008, we had cash and investments of $38.9 million, compared to cash and investments of $62.0 million at December 31, 2007; these figures include restricted investments of $1.0 million at September 30, 2008 and at December 31, 2007.

Based on our financial results in the first three quarters of 2008, the receipt of a $20 million upfront license fee from Alpharma in the fourth quarter of 2008 and a review of projections for the remainder of 2008, we are now revising our financial guidance for cash burn in 2008 from $32-36 million to approximately $10-12 million. Assuming that none of the other business development opportunities that we are currently pursuing close this year, we anticipate ending 2008 with more than $50 million in cash and investments.

"The first major event for us since the end of the second quarter was the granting of Priority Review status by the FDA of the New Drug Application (NDA) for REMOXY(R), which represents the first NDA filing for a product candidate based on one of DURECT's platform technologies," stated James E. Brown, D.V.M., President and CEO of DURECT. "The second major event for us was th
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
2. DURECT Corporation to Participate in Upcoming Healthcare Conferences
3. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
4. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
5. DURECT to Host Webcast in Conjunction with an Analysts Day on October 17
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. Verenium Corporation to Announce Third Quarter 2008 Financial Results
8. Environmental Tectonics Corporations Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety
9. AMERIGROUP Corporation Named One of Best Places to Work in Healthcare
10. STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results
11. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... launch product immediately, NATICK, Mass., April 17 ... announced that it has received approval for,the sale ... Canada. The Company reported that Health Canada,s Therapeutic,Products ... medical devices, has approved its use. The Company ...
... Syngenta today,announced that it will build a new biotech ... be on early-stage evaluation of GM and,native traits for ... areas of yield,improvement, drought resistance, disease control and biomass ... scope and will complement,Syngenta,s biotech research activities in the ...
... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor ... AACR,in San Diego today. The company presented data ... several novel, radicicol-based,Hsp90 inhibitors in its compound series., ... xenograft models,without evidence for liver and kidney toxicity. ...
Cached Biology Technology:Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 2Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 3Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... patients, own immune cells to target tumors have yielded promising ... also receive large doses of drugs designed to help immune ... Now a team of MIT engineers has devised a ... the backs of the cells sent in to fight the ...
... expensive DNA sequencing strategy, scientists have discovered genetic alterations ... rare disorder that causes multiple birth defects and mental ... new approach sequences just the exome, the 1-2 percent ... Kabuki syndrome, which has an estimated incidence of ...
... Stanley, Inc. (NYSE: www.stanleyassociates.com for ... this press release about our expectations about future ... the words "estimates," "anticipates," "plans," "expects" and similar ... the Private Securities Litigation Reform Act of 1995. ...
Cached Biology News:Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 2Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 3Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3
... FLISP Assay with FAM-Labeled Substrate (green ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
Request Info...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
Biology Products: